Annexon Inc Sustainability Reports
Annexon, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders. The company focuses on therapeutics to arrest C1q activation to treat autoimmune, neurodegenerative, and ophthalmic diseases.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG007QVDFH1
2 reports from 2020 to 2024
Company Profile
Annexon, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders. The company focuses on therapeutics to arrest C1q activation to treat autoimmune, neurodegenerative, and ophthalmic diseases.
Reports
2 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
